The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

EMJ

4 years
627 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0 to 100. This number indicates the likelihood that a woman's breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman's breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the Recurrence Score result of the Oncotype DX assay could influence treatment decisions, especially in the intermediate Recurrence Score group. She confirms, from her experience, that the Oncotype DX Recurrence Score result reduces physicians' and patients' anxiety regarding their optimal treatment decisions. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
1 Views
Cancer-News 35 minutes
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
5 Views
kidneycancer 18 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
4 Views
kidneycancer 20 hours
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
3 Views
CURC 22 hours
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 23 hours
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 23 hours
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 2 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 2 days